Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Thermo Fisher Scientific logoThermo Fisher Scientific TMO

Thermo Fisher Scientific issued 4 series of Senior Notes in a public offering on October 7, 2025: 2031 Notes $500,000,000, 2032 Notes $750,000,000, 2035 Notes $750,000,000 and 2037 Notes $500,000,000.

8-KEntry into a Material Definitive AgreementFiled Period of report Summary published (UTC)

Key points

AI summary
  1. Thermo Fisher Scientific issued 4 series of Senior Notes in a public offering on October 7, 2025: 2031 Notes $500,000,000, 2032 Notes $750,000,000, 2035 Notes $750,000,000 and 2037 Notes $500,000,000.

  2. The company disclosed interest rates on the Notes as 2031 Notes 4.200%, 2032 Notes 4.473%, 2035 Notes 4.794% and 2037 Notes 4.894%. The 2031 Notes mature on March 1, 2031, while the others mature on 2032, 2035 and October 7, 2037 respectively, with interest paid semi-annually in arrears.

  3. The company said that prior to the Par Call Date, it may redeem the Notes at the greater of 100% of the principal amount and the present value of remaining scheduled payments of principal and interest, and that upon a change of control coupled with a downgrade of the Notes below investment grade by at least two of the three major rating agencies, it will be required in certain circumstances to offer to repurchase the Notes at 101% of the principal amount.

  4. The company expects net proceeds from the offering of approximately $2.48 billion after deducting underwriting discounts and estimated offering expenses, and said it intends to use the net proceeds for general corporate purposes. It added that these may include acquisitions of companies or businesses, repayment and refinancing of debt, working capital, capital expenditures, or repurchase of its outstanding equity securities.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Public offering of 4 series of Senior Notes maturing in 2031, 2032, 2035 and 2037

Thermo Fisher Scientific issued 4 series of Senior Notes in a public offering on October 7, 2025: 2031 Notes $500,000,000, 2032 Notes $750,000,000, 2035 Notes $750,000,000 and 2037 Notes $500,000,000.

Source · Based on the filing body and exhibits

Interest rates and maturity dates by series, and interest payment dates

The company disclosed interest rates on the Notes as 2031 Notes 4.200%, 2032 Notes 4.473%, 2035 Notes 4.794% and 2037 Notes 4.894%. The 2031 Notes mature on March 1, 2031, while the others mature on 2032, 2035 and October 7, 2037 respectively, with interest paid semi-annually in arrears.

Source · Based on the filing body and exhibits

Early redemption terms and offer to repurchase at 101% upon change of control

The company said that prior to the Par Call Date, it may redeem the Notes at the greater of 100% of the principal amount and the present value of remaining scheduled payments of principal and interest, and that upon a change of control coupled with a downgrade of the Notes below investment grade by at least two of the three major rating agencies, it will be required in certain circumstances to offer to repurchase the Notes at 101% of the principal amount.

Source · Based on the filing body and exhibits

Net proceeds of approximately $2.48 billion and intended use

The company expects net proceeds from the offering of approximately $2.48 billion after deducting underwriting discounts and estimated offering expenses, and said it intends to use the net proceeds for general corporate purposes. It added that these may include acquisitions of companies or businesses, repayment and refinancing of debt, working capital, capital expenditures, or repurchase of its outstanding equity securities.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.